A Phase 3 interventional study of Placebo Matching Mitapivat and Mitapivat in Transfusion-dependent Alpha-Thalassemia and Transfusion-dependent Beta-Thalassemia, sponsored by Agios Pharmaceuticals, Inc.. Active, not recruiting at 75 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-28.
Sponsored by Agios Pharmaceuticals, Inc. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 91 studies in beta-Thalassemia with a site in United States — 22 open to participants now, 36 under way, 8 of them phase 3. beta-Thalassemia · United States.
Among the 91 studies in beta-Thalassemia with a site in United States, this one is the 5th largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2021, is one of 12 in phase 3, reaches primary completion later than 2 of the 35 other live ones, and was the 66th registered.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
Browse beta-Thalassemia studies →22 of the 91 studies in beta-Thalassemia with a site in United States are open now. Recruiting first, the newest first:
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
Agios Pharmaceuticals, Inc. · Sites in United States
Ages 1–17
National Heart, Lung, and Blood Institute (NHLBI) · Sites in United States
Ages 4–65
Daniel Bauer · Sites in United States
Ages 13–40
xCures · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 43 beta-Thalassemia studies recruiting now, 10 (23%) set no upper age limit and 31 (72%) stop at 75 or younger; 34 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
91 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 21 · Phase 2 41 · Phase 3 13 · Phase 4 2
First in 1995; this study’s year is marked. 7 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 258 is above the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Median enrollment 25 across the 71 interventional studies, 150 across the 17 observational. Of the 50 that completed or were terminated, 17 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
42 of 91 have an industry lead sponsor. The 10 most frequent:
Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.
Agios Pharmaceuticals, Inc. has 4 studies filed under beta-Thalassemia — fewer than ten, so there is no comparison to draw.
11 of the studies in beta-Thalassemia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05477563Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Efficacy and Safety of a Single Dose of CTX001 in Participants With Transfusion-Dependent β-Thalassemia and Severe Sickle Cell Disease | 2027-06-09 |
| NCT05356195Phase 3Vertex Pharmaceuticals IncorporatedEvaluation of Safety and Efficacy of CTX001 in Pediatric Participants With Transfusion-Dependent β-Thalassemia (TDT) | 2027-11-14 |
| NCT01962415Paul SzabolcsReduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT | 2026-11 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06421636Regeneron PharmaceuticalsA Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body | 2026-12-03 |
Add all 11 to your calendar (.ics) → With an account.
Among the 91 studies in beta-Thalassemia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary objective of this study was to compare the effect of mitapivat versus placebo on transfusion burden in participants with α- or β-transfusion-dependent thalassemia.
The mitapivat group included 171 participants. The placebo group included 87 participants.
294 studies on the registry are indexed under beta-Thalassemia; 69 are open to participants now.
This study's enrollment of 258 is above the median of 40 across 208 interventional studies indexed under beta-Thalassemia.
Browse beta-Thalassemia studies →Agios Pharmaceuticals, Inc. is the lead sponsor of 52 studies on the registry; 6 are open to participants now.
Of its 23 completed or terminated interventional studies of FDA-regulated products, 4 (17%) have results posted.
Compared within beta-Thalassemia, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Thalassemia. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Any medical, hematological, psychological, or behavioral condition(s) or prior or current therapy that, in the opinion of the Investigator, may confer an unacceptable risk to participating in the study and/or could confound the interpretation of the study data. Also excluded are:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CYP3A (CYP3A4) inhibitors and inducers
CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.
Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants randomized to receive mitapivat 100 milligrams (mg), orally, twice daily (BID) for 48 weeks in the double-blind (DB) period and for up to 5 years in the open label extension (OLE) period.
Drug: Mitapivat
Participants randomized to receive placebo matching mitapivat, orally, BID for 48 weeks in the DB period followed by mitapivat 100 mg, orally, BID for up to 5 years in the OLE period.
Drug: Placebo Matching Mitapivat · Drug: Mitapivat
Tablets
Tablets
Also known as: AG-348, AG-348 sulfate hydrate, Mitapivat sulfate
Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR)
TRR is defined as ≥50% reduction in transfused red blood cells (RBC) units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline transfusion burden standardized to 12 weeks. Baseline transfusion burden standardized to 12 weeks= (12/24) × total number of RBC units transfused during 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 12 (Day 85) were considered nonresponders.
Time frame: Double-blind Period: Baseline through Week 48
Double-blind Period: Percentage of Participants Who Achieved TRR2
TRR2, defined as a ≥50% reduction in transfused RBC units in any consecutive 24-week period through Week 48 compared with the 24-week baseline transfusion burden, is reported. Baseline transfusion burden standardized to 24 weeks is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 24 (Day 169) were considered nonresponders.
Time frame: Double-blind period: Baseline through Week 48
Double-blind Period: Percentage of Participants Who Achieved TRR3
TRR3, defined as a ≥33% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks= (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders.
Time frame: Double-blind period: Baseline up to Week 13 through Week 48
Double-blind Period: Percentage of Participants Who Achieved TRR4
TRR4, defined as a ≥50% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks = (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders.
Time frame: Double-blind period: Baseline up to Week 13 through Week 48
Double-blind Period: Percent Change From Baseline in Transfused RBC Units
Transfusion burden from Week 13 through Week 48 standardized to 36 weeks is defined as number of transfused RBC units from Day 85 through Week 48 in the Double-blind Period ×36/(Number of days from Day 85 through Week 48 in the Double-blind Period/7). Baseline transfusion burden standardized to 36 weeks= (36/24)× is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or within 168 days before the start of study treatment for participants randomized and dosed.
Time frame: Double-blind Period: Baseline, Week 13 through Week 48
Double-blind Period: Percentage of Participants Who Achieved Transfusion-Independence
Transfusion-independence is defined as transfusion-free for ≥8 consecutive weeks through Week 48 in the double-blind period.
Time frame: Double-blind Period: Baseline through Week 48
Double-blind Period: Change From Baseline in Iron Levels
Iron metabolism was assessed based on Iron levels.
Time frame: Double-blind Period: Baseline through Week 48
Double-blind Period: Change From Baseline in Serum Ferritin Levels
Iron metabolism was assessed based on serum ferritin levels.
Time frame: Double-blind Period: Baseline through Week 48
Double-blind Period: Change From Baseline in Total Iron Binding Capacity
Iron metabolism was assessed based on total iron binding capacity.
Time frame: Double-blind Period: Baseline through Week 48
Double-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels
Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity.
Time frame: Double-blind Period: Baseline through Week 48
Double-blind Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs, Related TEAEs and TEAEs With Severity Greater Than or Equal to Grade 3
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.
Time frame: Double-blind Period: From first dose of study drug up to week 48
Open-label Extension Period: Number of Participants With TEAEs, Serious TEAEs, Related TEAEs, Related TEAEs and TEAEs With Severity of Greater Than or Equal to 3
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.
Time frame: Open-Label Extension Period: From Week 48 up to end of study (approximately 5 years)
Double-blind Period: Plasma Concentrations of Mitapivat
Time frame: Double-blind Period: Pre-dose at Week 12; pre-dose at Week 24; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
Double-blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat
Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule.
Time frame: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
Double-blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat
Time frame: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
Double-blind Period: Time to Reach of Maximum Observed Plasma Concentration (Tmax) of Mitapivat
Time frame: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
Double-blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat
Time frame: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
Double-blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat
Clast is the last quantifiable concentration after a single dose or within the dosing interval (tau) for multiple doses.
Time frame: Double-blind Period: Pre-dose, 0.5, 1, 3, 5, 7 hours post-dose Week 36
Double-blind Period: Blood Concentration of Adenosine Triphosphate (ATP)
Time frame: Double-blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose at Week 24; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
Double-blind Period: Blood Concentration of 2,3 - Diphosphoglycerate (2,3-DPG)
Time frame: Double-blind Period: Pre-dose at Day 1; pre-dose at Week 12; pre-dose at Week 24; pre-dose, 0.5, 1, 3, 5, 7 hours post-dose at Week 36
Participants took part at 81 study sites in Malaysia,Taiwan,Thailand,Bulgaria,Brazil,Lebanon,Saudi Arabia,Turkey,United Arab Emirates,Canada, the United States,Denmark,France,Germany,Greece,Italy,Netherlands,Spain and the United Kingdom.Results are reported for 48-week DB period until primary completion date.Analysis of data for OLE period is still ongoing with anticipated completion in June 2029.Results for OLE period will be reported by June 2030.
| Milestone | Mitapivat | Placebo |
|---|---|---|
| Started | 171 | 87 |
| Safety analysis set | 172 | 85 |
| Completed | 155 | 83 |
| Not completed | 16 | 4 |
| Withdrew: Randomized, never treated | 0 | 1 |
| Withdrew: Adverse event | 9 | 1 |
| Withdrew: Withdrawal by subject | 7 | 1 |
| Withdrew: Pregnancy | 0 | 1 |
TRR is defined as ≥50% reduction in transfused red blood cells (RBC) units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through Week 48 compared with baseline transfusion burden standardized to 12 weeks. Baseline transfusion burden standardized to 12 weeks= (12/24) × total number of RBC units transfused during 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 12 (Day 85) were considered nonresponders.
| percentage of participants | Mitapivat | Placebo |
|---|---|---|
| Double-blind Period: Percentage of Participants Who Achieved Transfusion Reduction Response (TRR) | 30.4 | 12.6 |
TRR2, defined as a ≥50% reduction in transfused RBC units in any consecutive 24-week period through Week 48 compared with the 24-week baseline transfusion burden, is reported. Baseline transfusion burden standardized to 24 weeks is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 24 (Day 169) were considered nonresponders.
| percentage of participants | Mitapivat | Placebo |
|---|---|---|
| Double-blind Period: Percentage of Participants Who Achieved TRR2 | 13.5 | 2.3 |
TRR3, defined as a ≥33% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks= (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders.
| percentage of participants | Mitapivat | Placebo |
|---|---|---|
| Double-blind Period: Percentage of Participants Who Achieved TRR3 | 14.6 | 1.1 |
TRR4, defined as a ≥50% reduction in transfused RBC units from Week 13 through Week 48 compared with the baseline transfusion burden standardized to 36 weeks, is reported. Baseline transfusion burden standardized to 36 weeks = (36/24) × total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or the start of study treatment for participants randomized and dosed. Participants withdrawn from the study before Week 48 were considered nonresponders.
| percentage of participants | Mitapivat | Placebo |
|---|---|---|
| Double-blind Period: Percentage of Participants Who Achieved TRR4 | 7.6 | 1.1 |
Transfusion burden from Week 13 through Week 48 standardized to 36 weeks is defined as number of transfused RBC units from Day 85 through Week 48 in the Double-blind Period ×36/(Number of days from Day 85 through Week 48 in the Double-blind Period/7). Baseline transfusion burden standardized to 36 weeks= (36/24)× is the total number of RBC units transfused during the 24-week period before the randomization date for participants randomized and not dosed or within 168 days before the start of study treatment for participants randomized and dosed.
| percent change | Mitapivat | Placebo |
|---|---|---|
| Double-blind Period: Percent Change From Baseline in Transfused RBC Units | 10.96 ± 2.149 | 3.32 ± 2.846 |
Transfusion-independence is defined as transfusion-free for ≥8 consecutive weeks through Week 48 in the double-blind period.
| percentage of participants | Mitapivat | Placebo |
|---|---|---|
| Double-blind Period: Percentage of Participants Who Achieved Transfusion-Independence | 9.9 | 1.1 |
Iron metabolism was assessed based on Iron levels.
| micromoles per liter (µmol/L) | Mitapivat | Placebo |
|---|---|---|
| Double-blind Period: Change From Baseline in Iron Levels | -4.57 ± 0.949 | 2.06 ± 1.280 |
Iron metabolism was assessed based on serum ferritin levels.
| micrograms per liter (µg/L) | Mitapivat | Placebo |
|---|---|---|
| Double-blind Period: Change From Baseline in Serum Ferritin Levels | 45.3 ± 88.90 | 76.3 ± 119.84 |
Iron metabolism was assessed based on total iron binding capacity.
| µmol/L | Mitapivat | Placebo |
|---|---|---|
| Double-blind Period: Change From Baseline in Total Iron Binding Capacity | -21.80 ± 3.597 | -1.23 ± 5.053 |
Iron metabolism was assessed based on TSAT levels. Transferrin saturation is reported by dividing value of serum iron by total iron binding capacity.
| Ratio | Mitapivat | Placebo |
|---|---|---|
| Double-blind Period: Change From Baseline in Transferrin Saturation (TSAT) Levels | 0.079 ± 0.0261 | -0.013 ± 0.0371 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of AEs was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.
| Participants | Mitapivat | Placebo |
|---|---|---|
| Participants with TEAEs | 155 | 71 |
| Participants with serious TEAEs | 19 | 13 |
| Participants with TEAEs related to study drug | 65 | 16 |
| Participants with any TEAE of Grade ≥ 3 | 32 | 12 |
An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have a causal relationship with the study drug. A serious adverse event (SAE) is any untoward medical occurrence that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs are AEs with an initial onset date during the on-treatment period or worsening from baseline and includes both serious \& non-serious TEAEs. Severity of abnormalities was evaluated using the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE; Version 4.03): grade 1: mild; grade 2: moderate; grade 3: severe or medically significant but not immediately life-threatening; grade 4: life threatening or disabling; grade 5: death related to AE.
Results for this outcome have not been posted.
| nanograms per milliliter (ng/mL) | Mitapivat |
|---|---|
| Pre-dose at Week 12 | 122.90 ± 252.666 |
| Pre-dose at Week 24 | 96.55 ± 184.835 |
| Pre-dose at Week 36 | 129.31 ± 260.610 |
| 0.5 Hour Post-dose at Week 36 | 1282.21 ± 1007.068 |
| 1 Hour Post-dose at Week 36 | 1468.69 ± 713.248 |
| 3 Hours Post-dose at Week 36 | 765.32 ± 372.719 |
| 5 Hours Post-dose at Week 36 | 371.11 ± 232.556 |
| 7 Hours Post-dose at Week 36 | 221.78 ± 172.845 |
Area under the concentration-time curve from time zero to Tlast on dosing day, calculated using the linear-log trapezoidal rule.
| hours*nanograms per milliliter (h*ng/mL) | Mitapivat |
|---|---|
| Double-blind Period: Area Under the Plasma Concentration-time Curve From Time Zero to the Last Measurable Concentration (AUC0-last) of Mitapivat | 4365.84 ± 35.9 |
| nanograms per milliliter (ng/mL) | Mitapivat |
|---|---|
| Double-blind Period: Maximum Observed Plasma Concentration (Cmax) of Mitapivat | 1603.00 ± 45.6 |
| Hours | Mitapivat |
|---|---|
| Double-blind Period: Time to Reach of Maximum Observed Plasma Concentration (Tmax) of Mitapivat | 1.000 (0.42 to 5.00) |
| Hours | Mitapivat |
|---|---|
| Double-blind Period: Time of Last Quantifiable Concentration (Tlast) of Mitapivat | 6.750 (4.83 to 7.17) |
Clast is the last quantifiable concentration after a single dose or within the dosing interval (tau) for multiple doses.
| ng/mL | Mitapivat |
|---|---|
| Double-blind Period: Last Quantifiable Plasma Concentration (Clast) of Mitapivat | 175.76 ± 85.1 |
| µg/mL | Mitapivat | Placebo |
|---|---|---|
| Pre-dose at Day 1 | 224.33 ± 40.031 | 236.23 ± 47.368 |
| Pre-dose at Week 12 | 283.39 ± 59.217 | 204.19 ± 33.207 |
| Pre-dose at Week 24 | 279.16 ± 53.652 | 200.84 ± 30.333 |
| Pre-dose at Week 36 | 280.72 ± 61.834 | 210.47 ± 43.330 |
| 0.5 Hour Post-dose at Week 36 | 274.75 ± 63.513 | 206.83 ± 39.389 |
| 1 Hour Post-dose at Week 36 | 277.45 ± 58.668 | 209.92 ± 38.597 |
| 3 Hours Post-dose at Week 36 | 281.70 ± 61.262 | 213.63 ± 43.949 |
| 5 Hours Post-dose at Week 36 | 283.76 ± 61.216 | 208.18 ± 40.965 |
| 7 Hours Post-dose at Week 36 | 281.47 ± 57.163 | 212.02 ± 45.767 |
| µg/mL | Mitapivat | Placebo |
|---|---|---|
| Pre-dose at Day 1 | 426.67 ± 75.055 | 417.13 ± 87.448 |
| Pre-dose at Week 12 | 274.25 ± 76.114 | 365.88 ± 67.238 |
| Pre-dose at Week 24 | 275.60 ± 78.307 | 355.57 ± 59.420 |
| Pre-dose at Week 36 | 289.11 ± 78.658 | 368.81 ± 71.481 |
| 0.5 Hour Post-dose at Week 36 | 286.06 ± 73.409 | 367.74 ± 62.673 |
| 1 Hour Post-dose at Week 36 | 281.73 ± 80.276 | 368.67 ± 66.037 |
| 3 Hours Post-dose at Week 36 | 280.93 ± 76.916 | 383.00 ± 91.727 |
| 5 Hours Post-dose at Week 36 | 272.73 ± 65.327 | 359.09 ± 72.144 |
| 7 Hours Post-dose at Week 36 | 268.17 ± 65.942 | 369.19 ± 75.546 |
Collected over Double-blind period: From first dose of study drug up to week 48. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Mitapivat | 0/171 (0%) | 19/172 (11%) | 122/172 (70.9%) |
| Placebo | 0/87 (0%) | 13/85 (15.3%) | 50/85 (58.8%) |
| Event | Mitapivat | Placebo |
|---|---|---|
| PneumoniaInfections and infestations | 1/172 | 2/85 |
| Viral infectionInfections and infestations | 0/172 | 1/85 |
| Splenic haematomaBlood and lymphatic system disorders | 0/172 | 1/85 |
| CholecystitisHepatobiliary disorders | 1/172 | 1/85 |
| Cholecystitis acuteHepatobiliary disorders | 1/172 | 1/85 |
| Cholangitis acuteHepatobiliary disorders | 0/172 | 1/85 |
| ArrhythmiaCardiac disorders | 0/172 | 1/85 |
| Left ventricular dysfunctionCardiac disorders | 0/172 | 1/85 |
| Infusion related reactionInjury, poisoning and procedural complications | 0/172 | 1/85 |
| CataractEye disorders | 0/172 | 1/85 |
| Event | Mitapivat | Placebo |
|---|---|---|
| HeadacheNervous system disorders | 46/172 | 10/85 |
| Upper respiratory tract infectionInfections and infestations | 27/172 | 14/85 |
| Initial insomniaPsychiatric disorders | 24/172 | 4/85 |
| DiarrhoeaGastrointestinal disorders | 19/172 | 7/85 |
| FatigueGeneral disorders | 18/172 | 2/85 |
| PyrexiaGeneral disorders | 17/172 | 6/85 |
| COVID-19Infections and infestations | 8/172 | 8/85 |
| CoughRespiratory, thoracic and mediastinal disorders | 15/172 | 3/85 |
| VomitingGastrointestinal disorders | 8/172 | 7/85 |
| InfluenzaInfections and infestations | 14/172 | 4/85 |
Full analysis set (FAS) included all participants who were randomized.
| Age, Continuous(years) | Mitapivat | Placebo | Total |
|---|---|---|---|
| Mean | 35.8 ± 11.61 | 34.7 ± 9.77 | 35.5 ± 11.02 |
| Sex: Female, Male(Participants) | Mitapivat | Placebo | Total |
|---|---|---|---|
| Female | 93 | 43 | 136 |
| Male | 78 | 44 | 122 |
| Ethnicity (NIH/OMB)(Participants) | Mitapivat | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 5 | 3 | 8 |
| Not Hispanic or Latino | 158 | 79 | 237 |
| Unknown or Not Reported | 8 | 5 | 13 |
| Race/Ethnicity, Customized(Participants) | Mitapivat | Placebo | Total |
|---|---|---|---|
| White | 99 | 56 | 155 |
| Asian | 56 | 22 | 78 |
| Black or African American | 1 | 1 | 2 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Multiracial | 2 | 0 | 2 |
| Unknown | 7 | 3 | 10 |
| Not reported | 6 | 5 | 11 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Nov 2021 to primary completion in Apr 2024, 28 months.
Results were first posted in May 2025, 1 year 1 month after primary completion.
Of 18 phase 3 interventional studies under beta-Thalassemia, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 67. This study's 28 months is below that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mitapivat